Year |
Citation |
Score |
2019 |
Yang L, Li Y, Bhattacharya A, Zhang Y. A recombinant human protein targeting HER2 overcomes drug resistance in HER2-positive breast cancer. Science Translational Medicine. 11. PMID 30674653 DOI: 10.1126/Scitranslmed.Aav1620 |
0.339 |
|
2018 |
Rustum YM, Chintala S, Durrani FA, Bhattacharya A. Non-Coding Micro RNAs and Hypoxia-Inducible Factors Are Selenium Targets for Development of a Mechanism-Based Combination Strategy in Clear-Cell Renal Cell Carcinoma-Bench-to-Bedside Therapy. International Journal of Molecular Sciences. 19. PMID 30380599 DOI: 10.3390/Ijms19113378 |
0.393 |
|
2018 |
Zakharia Y, Bhattacharya A, Rustum YM. Selenium targets resistance biomarkers enhancing efficacy while reducing toxicity of anti-cancer drugs: preclinical and clinical development. Oncotarget. 9: 10765-10783. PMID 29535842 DOI: 10.18632/Oncotarget.24297 |
0.403 |
|
2018 |
Yang L, Li Y, Bhattacharya A, Zhang Y. Abstract 552: PEPD is an essential regulator of p53 tumor suppressor Cancer Research. 78: 552-552. DOI: 10.1158/1538-7445.Am2018-552 |
0.308 |
|
2016 |
Yang L, Li Y, Bhattacharya A, Zhang Y. Dual inhibition of ErbB1 and ErbB2 in cancer by recombinant human prolidase mutant hPEPD-G278D. Oncotarget. PMID 27286447 DOI: 10.18632/Oncotarget.9851 |
0.377 |
|
2015 |
Veeranki OL, Bhattacharya A, Tang L, Marshall JR, Zhang Y. Cruciferous vegetables, isothiocyanates, and prevention of bladder cancer. Current Pharmacology Reports. 1: 272-282. PMID 26273545 DOI: 10.1007/S40495-015-0024-Z |
0.381 |
|
2015 |
Yang L, Li Y, Bhattacharya A, Zhang Y. Inhibition of ERBB2-overexpressing Tumors by Recombinant Human Prolidase and Its Enzymatically Inactive Mutant. Ebiomedicine. 2: 396-405. PMID 26086037 DOI: 10.1016/J.Ebiom.2015.03.016 |
0.41 |
|
2015 |
Yang L, Li Y, Bhattacharya A, Zhang Y. Abstract P6-07-04: Targeting ErbB2 with human PEPD Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-P6-07-04 |
0.367 |
|
2013 |
Bhattacharya A, Li Y, Shi Y, Zhang Y. Enhanced inhibition of urinary bladder cancer growth and muscle invasion by allyl isothiocyanate and celecoxib in combination. Carcinogenesis. 34: 2593-9. PMID 23946495 DOI: 10.1093/Carcin/Bgt280 |
0.399 |
|
2012 |
Bhattacharya A, Li Y, Geng F, Munday R, Zhang Y. The principal urinary metabolite of allyl isothiocyanate, N-acetyl-S-(N-allylthiocarbamoyl)cysteine, inhibits the growth and muscle invasion of bladder cancer. Carcinogenesis. 33: 394-8. PMID 22131350 DOI: 10.1093/Carcin/Bgr283 |
0.356 |
|
2011 |
Azrak RG, Cao S, Durrani FA, Toth K, Bhattacharya A, Rustum YM. Augmented therapeutic efficacy of irinotecan is associated with enhanced drug accumulation. Cancer Letters. 311: 219-29. PMID 21872389 DOI: 10.1016/J.Canlet.2011.07.023 |
0.417 |
|
2011 |
Bhattacharya A. Methylselenocysteine: a promising antiangiogenic agent for overcoming drug delivery barriers in solid malignancies for therapeutic synergy with anticancer drugs. Expert Opinion On Drug Delivery. 8: 749-63. PMID 21473705 DOI: 10.1517/17425247.2011.571672 |
0.368 |
|
2011 |
Bhattacharya A, Turowski SG, San Martin ID, Rajput A, Rustum YM, Hoffman RM, Seshadri M. Magnetic resonance and fluorescence-protein imaging of the anti-angiogenic and anti-tumor efficacy of selenium in an orthotopic model of human colon cancer. Anticancer Research. 31: 387-93. PMID 21378316 |
0.311 |
|
2011 |
Bhattacharya A, Turowski SG, Martin IDS, Rajput A, Rustum YM, Hoffman RM, Seshadri M. Abstract 4284: Combined magnetic resonance and fluorescence-protein imaging to simultaneously assess the anti-tumor and anti-angiogenesis efficacy of selenium Cancer Research. 71: 4284-4284. DOI: 10.1158/1538-7445.Am2011-4284 |
0.405 |
|
2010 |
Bhattacharya A, Li Y, Wade KL, Paonessa JD, Fahey JW, Zhang Y. Allyl isothiocyanate-rich mustard seed powder inhibits bladder cancer growth and muscle invasion. Carcinogenesis. 31: 2105-10. PMID 20889681 DOI: 10.1093/Carcin/Bgq202 |
0.359 |
|
2010 |
Chintala S, Tóth K, Yin MB, Bhattacharya A, Smith SB, Ola MS, Cao S, Durrani FA, Zinia TR, Dean R, Slocum HK, Rustum YM. Downregulation of cystine transporter xc by irinotecan in human head and neck cancer FaDu xenografts. Chemotherapy. 56: 223-33. PMID 20551639 DOI: 10.1159/000316334 |
0.368 |
|
2010 |
Rustum YM, Tóth K, Seshadri M, Sen A, Durrani FA, Stott E, Morrison CD, Cao S, Bhattacharya A. Architectural heterogeneity in tumors caused by differentiation alters intratumoral drug distribution and affects therapeutic synergy of antiangiogenic organoselenium compound. Journal of Oncology. 2010: 396286. PMID 20445750 DOI: 10.1155/2010/396286 |
0.404 |
|
2010 |
Bhattacharya A, Tang L, Li Y, Geng F, Paonessa JD, Chen SC, Wong MK, Zhang Y. Inhibition of bladder cancer development by allyl isothiocyanate. Carcinogenesis. 31: 281-6. PMID 19955395 DOI: 10.1093/Carcin/Bgp303 |
0.366 |
|
2010 |
Bhattacharya A, Tang L, Geng F, Paonessa JD, Chen SC, Wong MKK, Zhang Y. Abstract A73: Bladder cancer inhibition by allyl isothiocyante Cancer Prevention Research. 3. DOI: 10.1158/1940-6207.Prev-09-A73 |
0.361 |
|
2009 |
Bhattacharya A, Tóth K, Sen A, Seshadri M, Cao S, Durrani FA, Faber E, Repasky EA, Rustum YM. Inhibition of colon cancer growth by methylselenocysteine-induced angiogenic chemomodulation is influenced by histologic characteristics of the tumor. Clinical Colorectal Cancer. 8: 155-62. PMID 19632930 DOI: 10.3816/Ccc.2009.N.025 |
0.424 |
|
2008 |
Bhattacharya A, Tóth K, Durrani FA, Cao S, Slocum HK, Chintala S, Rustum YM. Hypoxia-specific drug tirapazamine does not abrogate hypoxic tumor cells in combination therapy with irinotecan and methylselenocysteine in well-differentiated human head and neck squamous cell carcinoma a253 xenografts. Neoplasia (New York, N.Y.). 10: 857-65. PMID 18670644 DOI: 10.1593/Neo.08424 |
0.448 |
|
2008 |
Bhattacharya A, Seshadri M, Oven SD, Tóth K, Vaughan MM, Rustum YM. Tumor vascular maturation and improved drug delivery induced by methylselenocysteine leads to therapeutic synergy with anticancer drugs. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 3926-32. PMID 18559614 DOI: 10.1158/1078-0432.Ccr-08-0212 |
0.434 |
|
2006 |
Seshadri M, Mazurchuk R, Spernyak JA, Bhattacharya A, Rustum YM, Bellnier DA. Activity of the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid against human head and neck carcinoma xenografts. Neoplasia (New York, N.Y.). 8: 534-42. PMID 16867215 DOI: 10.1593/Neo.06295 |
0.627 |
|
2004 |
Bhattacharya A, Tóth K, Mazurchuk R, Spernyak JA, Slocum HK, Pendyala L, Azrak R, Cao S, Durrani FA, Rustum YM. Lack of microvessels in well-differentiated regions of human head and neck squamous cell carcinoma A253 associated with functional magnetic resonance imaging detectable hypoxia, limited drug delivery, and resistance to irinotecan therapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 8005-17. PMID 15585636 DOI: 10.1158/1078-0432.Ccr-04-1306 |
0.597 |
|
Show low-probability matches. |